Coronavirus vaccine safe in early trial; hydroxychloroquine may increase death risk




  • In US
  • 2020-05-22 19:01:06Z
  • By Reuters
Coronavirus vaccine safe in early trial; hydroxychloroquine may increase death risk
Coronavirus vaccine safe in early trial; hydroxychloroquine may increase death risk  

By Nancy Lapid

(Reuters) - The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.


Coronavirus vaccine appears safe in first-in-human trial

A coronavirus vaccine developed by CanSino Biologics Inc appears to be safe and induced a rapid immune response in its first human trial, Chinese researchers reported on Friday in The Lancet medical journal. First-in-human studies, known as Phase I trials, are primarily designed to test safety. This vaccine did not cause any serious adverse effects, the researchers say. Furthermore, blood samples from the 108 vaccinated adults showed so-called neutralizing antibodies and T-cell responses against the novel coronavirus, a sign of possible efficacy. "These results represent an important milestone," coauthor Professor Wei Chen from the Beijing Institute of Biotechnology said in a statement. "The ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19. We are still a long way from this vaccine being available to all," the researcher added. Further studies will be needed to confirm whether the vaccine protects against infection. The first such trial is underway in Wuhan, China. (; https://reut.rs/36lvRD0; https://bit.ly/3cX8h1X )


Hydroxychloroquine tied to higher death risk in hospitalized patients

In an observational study of more than 96,000 COVID-19 patients at 671 hospitals on six continents, the malaria drug hydroxychloroquine was tied to an increased risk of death, researchers reported on Friday. It was not clear whether taking the drug provided patients with any benefit, according to their paper in The Lancet. Overall, 14,888 patients received hydroxychloroquine or chloroquine, with or without an antibiotic, and 81,144 did not receive those drugs. Randomized placebo-controlled studies are needed to clarify the risks and benefits of the decades-old drug in the treatment of COVID-19, the researchers said. Many such trials are underway. The University of Minnesota may have some results next week, from two studies testing whether hydroxychloroquine is useful for preventing infection in people exposed to the virus and whether it alleviates COVID-19 symptoms. Other placebo-controlled trial results are expected starting later this summer. (; https://reut.rs/2WXnbQp; https://bit.ly/2ynpT86 )


Simulated sunlight inactivates the coronavirus on surfaces

Simulated sunlight rapidly inactivates the novel coronavirus on non-porous surfaces like stainless steel, according to researchers from the Department of Homeland Security Science and Technology Directorate's National Biodefense Analysis and Countermeasures Center (NBACC). "These results suggest that natural sunlight may be effective for significantly reducing the amount of virus on exposed surfaces, such as mailboxes, playground equipment, and shopping carts left outdoors in the sunlight," a spokesman for the researchers told Reuters. While significant reductions of the virus were observed after just a few minutes of simulated sunlight, the risk of exposure from contact with surfaces may not be fully eliminated, the researchers cautioned in the Journal of Infectious Diseases. More research is needed on how much virus is shed onto surfaces from infected individuals, how easily the virus is transferred from surfaces, and what amount is needed to cause infection. (https://bit.ly/3e4cxNg )


Hold off on blanket 'DNR' orders for critically ill COVID patients

In the desperate early days of the coronavirus pandemic, reports from China that few critically ill COVID-19 patients could be revived after a cardiac arrest led doctors in some countries to consider issuing blanket "Do Not Resuscitate" orders. But for U.S. COVID-19 patients, at least, that would not be appropriate, researchers said. Adequate data is not yet available on U.S. survival rates for in-hospital resuscitation of COVID-19 patients and the Chinese data may not be applicable, researchers wrote in a paper published on Friday in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal. "Early experience of the pandemic in the U.S. reveals that about a quarter of COVID-19 patients are younger than 50 years of age and otherwise healthy. Cardiac arrest in such patients will likely have a different prognosis" than it would in older patients, researchers said. The study authors are members of the American Heart Association "Get With The Guidelines" Resuscitation Investigators panel. (https://bit.ly/3gaxBDI )




(Reporting by Nancy Lapid, Deena Beasley, Ankur Banerjee and Michael Erman; Editing by Bill Berkrot)

COMMENTS

More Related News

New coronavirus losing potency, top Italian doctor says
New coronavirus losing potency, top Italian doctor says

The new coronavirus is losing its potency and has become much less lethal, a senior Italian doctor said on Sunday. "In reality, the virus clinically no longer exists in Italy," said Alberto Zangrillo, the head of the San Raffaele Hospital in Milan in the northern region of Lombardy, which has borne the brunt of Italy's coronavirus contagion. Italy has the third highest death toll in the world from COVID-19, with 33,415 people dying since the outbreak came to light on Feb. 21.

Vaccine and coronavirus skeptics packed into a hotel for a conference over Memorial Day weekend, defying guidelines
Vaccine and coronavirus skeptics packed into a hotel for a conference over Memorial Day weekend, defying guidelines

200 alternative medicine practitioners and followers attended a conference in a North Carolina hotel over Memorial Day weekend, defying guidelines.

Coronavirus updates: New Jersey allows in-person graduations; Costco
Coronavirus updates: New Jersey allows in-person graduations; Costco's free samples are coming back; Trump to scrap relationship with WHO

President Trump blasted the World Health Organization. NYC is on track to begin reopening in June. Consumer spending sank. More COVID-19 news Friday.

Black voters don
Black voters don't trust mail ballots. That's a problem for Democrats
  • US
  • 2020-05-29 11:02:51Z

Sharon Fason used to accompany her mother to their south Chicago polling place every Election Day as a little girl, watching as she joined their African-American neighbors in the hard-won right of casting a ballot. The Democratic Party is pushing mail-in voting as the safest way to cast ballots amid the coronavirus pandemic.

U.S. hospitals slash use of drug championed by Trump as coronavirus treatment
U.S. hospitals slash use of drug championed by Trump as coronavirus treatment
  • US
  • 2020-05-29 10:08:05Z

U.S. hospitals said they have pulled way back on the use of hydroxychloroquine, the malaria drug touted by President Donald Trump as a COVID-19 treatment, after several studies suggested it is not effective and may pose significant risks. Several hospitals that two months ago told Reuters they were using hydroxychloroquine frequently for patients with COVID-19 have cut back. Orders for the drug have dropped to a tenth of the late-March peak, to about 125,000 pills last week, said Vizient Inc, a drug buyer for about half of U.S. hospitals.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US